0.95
0.95 (0%)
As of Apr 17, 2025
Esperion Therapeutics, Inc. [ESPR]
Source:
Company Overview
Esperion is a commercial stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. We have developed and are commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease, or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C.
| Country | United States |
| Headquarters | ann arbor, michigan |
| Phone Number | 734-887-3903 |
| Industry | manufacturing |
| CEO | Sheldon L. Koenig |
| Website | www.linkedin.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $332.3 |
| Operating Profit | $54.4 |
| Net Income | $-51.7 |
| Net Cash | $62.5 |
Profit Ratios
| Gross Margin | $263.7 |
| Operating Margin | 16.4 |
| Profit as % of Revenues | -509.6% |
| Profit as % of Assets | -18.8% |
| Profit as % of Stockholder Equity | 13.3% |
Management Effectiveness
| Return on Equity | 13.3% |
| Return on Assets | -15.1% |
| Turnover Ratio | 120.9% |
| EBITA | $54.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $343.8 |
| Total Liabilities | $732.5 |
| Operating Cash Flow | $-23.7 |
| Investing Cash Flow | $-0.3 |
| Financing Cash Flow | $86.5 |
